Systems and methods for treating medical conditions by stimulation of medial thalamic region

Patent metadata

Field	Value
Publication number	US-9539425-B2
Application number	US-87172707-A
Country	US
Kind code	B2
Filing date	Oct 12, 2007
Priority date	Oct 13, 2006
Publication date	Jan 10, 2017
Grant date	Jan 10, 2017

Abstract

A system for treating medical conditions by neuromodulation of one or more target sites in the nervous system. In certain embodiments, at least one of the target sites is the medial thalamic region, including the intralaminar nucleus and the adjacent white and grey matter. In certain embodiments, where there is more than one target site, the other target sites is elsewhere in the nervous system, including the globus pallidus interna, subthalamic nucleus, corpus callosum, cerebellum, cerebral cortex (including the premotor cortex, motor cortex, and sensory cortex), ventral striatum, lateral thalamus, substantia nigra, and pedunculopontine nuclei. The medical conditions include movement disorders or improvement of movement function, stroke, neuropsychiatric or neuropsychologic disorders, neurodevelopmental disorders, and pain. Methods for treating medical conditions by neuromodulation of the intralaminar nuclei either alone or in combination with another target site(s) is also provided.

First claim

We claim:

1. A method of treating a condition selected from the group consisting of: a movement disorder or improvement of movement function, wherein the method comprises:
sensing neuronal electrical activity from a sensor placed in intralaminar nuclei of a patient;
delivering, in response to the sensing, a first stimulus to a first target site that is the intralaminar nuclei of the patient; and
delivering a second stimulus to a second target site selected from the group consisting of a globus pallidus interna, lateral thalamus, substantia nigra, pedunculopontine nuclei, premotor cortex, motor cortex, and sensory cortex, wherein the condition being treated is a movement disorder or improvement of movement function affected by the movement disorder.

2. The method of claim 1 , wherein the second target site is selected from the group consisting of the pedunculopontine nuclei, premotor cortex, motor cortex, and sensory cortex.

3. The method of claim 1 , further comprising positioning a first therapy delivery device at the intralaminar nuclei, and delivering the first stimulus through the first therapeutic delivery device.

4. The method of claim 3 , wherein the first therapy delivery device is a drug port.

5. The method of claim 4 , wherein the first therapy delivery device is an electrode.

6. The method of claim 5 , wherein delivering the first stimulus through the electrode causes localized tissue damage at the first target site.

7. The method of claim 4 , wherein sensing neuronal electrical activity comprises sensing the neuronal electrical activity using the first therapy delivery device positioned at the intralaminar nuclei.

8. The method of claim 1 , wherein the movement disorder is selected from the group consisting of Parkinson's disorder, dystonia, tremor, and spasticity.

9. The method of claim 1 , wherein the movement function is postural stability, gait, limb movement, balance, speech, swallowing, control of axial musculature, or autonomic control.

10. The method of claim 1 , wherein the delivery of the first stimulus and delivery of the second stimulus are coordinated.

11. The method of claim 10 , wherein the delivery of the first stimulus and delivery of the second stimulus are simultaneous.

12. The method of claim 10 , wherein the delivery of the first stimulus and delivery of the second stimulus are alternating.

13. The method of claim 10 , wherein the delivery of the first stimulus and delivery of the second stimulus are time-delayed.

14. The method of claim 1 , wherein the second target site is the globus pallidus interna.

15. The method of claim 14 , further comprising delivering a third stimulus to a subthalamic nucleus.

Assignees

• Rezai Ali
• Schiff Nicholas
• Kokones Scott
• Machado Andre
• Farris Sierra
• Intelect Medical Inc
• Cleveland Clinic Found
• Cornell Res Foundation Inc

Inventors

• Rezai Ali
• Schiff Nicholas
• Kokones Scott
• Machado Andre
• Farris Sierra

Classifications

• A61N1/36082

  Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease · CPC title

• A61N1/361 Primary

  Phantom sensations, e.g. tinnitus · CPC title

• A61N1/36017

  with leads or electrodes penetrating the skin · CPC title

• A61N1/36025

  for treating a mental or cerebral condition · CPC title